English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Over the past two decades, monoclonal antibodies have emerged as a versatile class of therapeutics with unique properties. More than30 therapeutic antibodies are now approved in the United States and European Union, with numerous candidates filling the preclinical andclinical pipeline of every major pharmaceutical companies and biotechnology firms. Monoclonal antibodies have the advantage over traditionalmedicines in that they are able to specifically bind to the desired targets with little to no associated toxicity. In the recent years, monoclonalantibodies approved for oncology treatments have gained in notoriety and are now used as adjuvants or neo-adjuvants to radiotherapy,chemotherapy and surgery. In the field of head and neck cancer, the anti-EGF receptor antibody Erbitux has paved the way for new targetedtreatments to SCCHN. This review introduces some basic concepts and recent perspectives on monoclonal antibodies with a focus on headand neck cancer treatments.

Therapeutic Monoclonal Antibodies: Current Perspectives and Applications for the Treatment of Head and Neck Cancer